• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Wednesday

    3/30/22 12:42:03 PM ET
    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABOS alert in real time by email

     

     

    On Wednesday, 29 stocks hit new 52-week lows.

    Interesting Points From Today's 52-Week Lows:

    • The largest company in terms of market cap to set a new 52-week low was Tempur Sealy Intl (NYSE:TPX).
    • Stryve Foods (NASDAQ:SNAX) was the smallest company when considering market cap to set a new 52-week low.
    • Revelation Biosciences (NASDAQ:REVB) saw the most significant move of the companies, as shares traded down 40.67% to reach its new 52-week low.
    • Incannex Healthcare (NASDAQ:IXHL) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low.

    On Wednesday, the following stocks hit new 52-week lows:

    • Tempur Sealy Intl (NYSE:TPX) shares set a new 52-week low of $29.01. The stock traded down 4.94%.
    • Embecta (NASDAQ:EMBCV) stock set a new 52-week low of $38.00 on Wednesday, moving down 3.75%.
    • Cue Health (NASDAQ:HLTH) shares reached a new 52-week low of $6.42 on Wednesday morning, moving down 1.49%.
    • Aveanna Healthcare Hldgs (NASDAQ:AVAH) shares moved down 1.03% on Wednesday to hit a new 52-week low of $3.80, drifting down 1.03%.
    • Torrid Holdings (NYSE:CURV) stock hit a yearly low of $6.62. The stock was down 2.35% for the day.
    • Sight Sciences (NASDAQ:SGHT) shares set a new 52-week low of $12.66. The stock traded down 9.33%.
    • Arcellx (NASDAQ:ACLX) stock broke to a new 52-week low of $13.47 on Wednesday. Shares of the company traded down 0.71%.
    • Incannex Healthcare (NASDAQ:IXHL) shares made a new 52-week low of $9.30 on Wednesday. The stock was 0.0% (flat) for the day.
    • DWS Municipal IT (NYSE:KTF) stock broke to a new 52-week low of $10.01 on Wednesday. Shares of the company traded up 0.96%.
    • Anghami (NASDAQ:ANGH) stock achieved a new 52-week low on Wednesday morning, hitting $9.27 and moving down 0.84%.
    • Airspan Networks Hldgs (AMEX:MIMO) stock drifted down 1.95% on Wednesday morning to hit a new 52-week low of $2.83.
    • UpHealth (NYSE:UPH) stock achieved a new 52-week low on Wednesday morning, hitting $1.31 and moving down 29.79%.
    • Acumen Pharmaceuticals (NASDAQ:ABOS) stock hit a yearly low of $4.10. The stock was down 5.48% for the day.
    • Galiano Gold (AMEX:GAU) stock achieved a new 52-week low on Wednesday morning, hitting $0.52 and moving down 4.57%.
    • Kirkland's (NASDAQ:KIRK) stock hit a yearly low of $9.65. The stock was down 5.5% for the day.
    • Annexon (NASDAQ:ANNX) stock dropped to a yearly low on Wednesday of $2.91. Shares traded up 0.84%.
    • Accelerate Diagnostics (NASDAQ:AXDX) shares made a new 52-week low of $1.40 on Wednesday. The stock was down 5.07% for the day.
    • Applied Genetic (NASDAQ:AGTC) stock dropped to a yearly low on Wednesday of $1.10. Shares traded down 0.45%.
    • Inpixon (NASDAQ:INPX) shares set a new 52-week low of $0.24. The stock traded down 9.46%.
    • Coffee Holding Co (NASDAQ:JVA) shares set a new 52-week low of $3.40. The stock traded down 1.1%.
    • Revelation Biosciences (NASDAQ:REVB) shares set a new yearly low of $0.70 this morning. The stock was down 40.67% on the session.
    • HTG Molecular Diagnostics (NASDAQ:HTGM) stock hit $1.42 on Wednesday morning, setting a new 52-week low for a change of down 3.94%.
    • Stryve Foods (NASDAQ:SNAX) stock achieved a new 52-week low on Wednesday morning, hitting $1.32 and moving down 10.0%.

    Be sure to monitor Benzinga for the news traders need! And for even more up-to-date info on 52-week lows and highs, check out Benzinga Pro. This cutting-edge market research platform alerts traders of which stocks are trading near their 52-week highs and lows each morning - and delivers lots of other actionable data. Learn more here.

    Get the next $ABOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABOS
    $ACLX
    $AGTC
    $ANGH

    CompanyDatePrice TargetRatingAnalyst
    Arcellx Inc.
    $ACLX
    1/7/2026$100.00Buy
    UBS
    Sight Sciences Inc.
    $SGHT
    1/5/2026$9.00Neutral → Overweight
    Piper Sandler
    Annexon Inc.
    $ANNX
    12/23/2025$16.00Buy
    Chardan Capital Markets
    Arcellx Inc.
    $ACLX
    12/22/2025$100.00Overweight
    Wells Fargo
    Aveanna Healthcare Holdings Inc.
    $AVAH
    12/8/2025Outperform
    William Blair
    Arcellx Inc.
    $ACLX
    11/18/2025Peer Perform
    Wolfe Research
    Aveanna Healthcare Holdings Inc.
    $AVAH
    11/13/2025$11.00Outperform
    BMO Capital Markets
    Torrid Holdings Inc.
    $CURV
    10/24/2025Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $20,657 worth of shares (4,115 units at $5.02), increasing direct ownership by 8% to 54,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    1/2/26 4:30:06 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Encrantz Staffan bought $115,963 worth of shares (13,958 units at $8.31), increasing direct ownership by 1% to 1,391,922 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    12/18/25 6:10:08 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Director Carson William H. bought $18,394 worth of shares (4,115 units at $4.47), increasing direct ownership by 9% to 50,290 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    12/3/25 4:30:14 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on Arcellx with a new price target

    UBS resumed coverage of Arcellx with a rating of Buy and set a new price target of $100.00

    1/7/26 9:34:38 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sight Sciences upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sight Sciences from Neutral to Overweight and set a new price target of $9.00

    1/5/26 8:36:47 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Chardan Capital Markets initiated coverage on Annexon with a new price target

    Chardan Capital Markets initiated coverage of Annexon with a rating of Buy and set a new price target of $16.00

    12/23/25 8:41:58 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roper Jess covered exercise/tax liability with 1,591 shares, decreasing direct ownership by 11% to 12,828 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    2/5/26 5:31:20 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chawla Lakhmir S covered exercise/tax liability with 2,261 shares, decreasing direct ownership by 16% to 12,158 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    2/5/26 5:30:45 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carver Jennifer covered exercise/tax liability with 1,661 shares, decreasing direct ownership by 12% to 12,758 units (SEC Form 4)

    4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

    2/5/26 5:30:12 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    SEC Filings

    View All

    SEC Form N-CEN filed by DWS Municipal Income Trust

    N-CEN - DWS MUNICIPAL INCOME TRUST (0000839533) (Filer)

    2/9/26 3:43:10 PM ET
    $KTF
    Finance Companies
    Finance

    SEC Form PRE 14A filed by Revelation Biosciences Inc.

    PRE 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    2/6/26 4:32:19 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcellx Inc.

    SCHEDULE 13G/A - Arcellx, Inc. (0001786205) (Subject)

    2/5/26 1:16:32 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel's D-Domain Binder

    -- CAR constructs representative of anito-cel (D-Domain), cilta-cel (dual VHH), and ide-cel (scFv) were assessed preclinically for tonic signaling and off-target Claudin binding -- -- No tonic signaling or off-target activity was observed with the D-Domain, supporting its unique target-specific binding profile and anito-cel's potentially best-in-class safety profile -- -- Specific off-target activity against Claudin-9 was observed with the dual VHH binder, consistent with cilta-cel's publicly available regulatory assessment reports; the D-Domain and scFv binders did not demonstrate off-target activity -- -- CAR T activation and cytokine release were observed for dual VHH and scFv bind

    2/4/26 9:00:00 AM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

    MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board ("CAB"): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The addition of Drs. Stein, Cutler, and Kalali further strengthens the Board's expertise across psychiatry, neurobiology, psychopharmacology, an

    1/29/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galiano Gold Expands Abore High-Grade Footprint with Multiple Intercepts in Latest Drilling Including 14.2 g/t Au over 15m and 4.7 g/t Au over 24m

    New high-grade intercepts expand mineralized footprint well below existing drilling, results will be included in upcoming Abore maiden underground Mineral ResourceVancouver, British Columbia--(Newsfile Corp. - January 29, 2026) - Galiano Gold Inc. (TSX:GAU) (NYSE:GAU) ("Galiano" or the "Company") is pleased to report the latest results of the 2025 Abore drilling program, which was completed in December 2025 at the Asanko Gold Mine ("AGM") in Ghana, West Africa. Multiple intercepts demonstrate continuity of high-grade zones and step out drilling confirms new high-grade mineralization up to 200 meters ("m") below previous holes. These results demonstrate the robustness of Abore's underground p

    1/29/26 7:30:00 AM ET
    $GAU
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Leadership Updates

    Live Leadership Updates

    View All

    Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

    MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board ("CAB"): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The addition of Drs. Stein, Cutler, and Kalali further strengthens the Board's expertise across psychiatry, neurobiology, psychopharmacology, an

    1/29/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

    NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced George Golumbeski, Ph.D., has joined its Board of Directors as Chairman. Dr. Golumbeski brings more than 30 years of experience in the biopharmaceuticals industry, with extensive expertise in portfolio strategy, strategic collaborations and licensing, and M&A. The addition of Dr. Golumbeski brings the Acumen Board to eight members. "I am very pleased to welcome Dr. Golumbeski to th

    11/10/25 8:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

    MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of Alison (Ali) Bauerlein as its Chief Operating Officer (COO) and James (Jim) Rodberg as its Chief Financial Officer (CFO), effective November 5, 2025. "We are very excited to promote both Ali and Jim into new roles at Sight Sciences as we continue to elevate our market leadership position in MIGS and begin to scale the reimbursed interventional dry eye category. We believe the many contribu

    11/6/25 4:04:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Financials

    Live finance-specific insights

    View All

    Galiano Gold Expands Abore High-Grade Footprint with Multiple Intercepts in Latest Drilling Including 14.2 g/t Au over 15m and 4.7 g/t Au over 24m

    New high-grade intercepts expand mineralized footprint well below existing drilling, results will be included in upcoming Abore maiden underground Mineral ResourceVancouver, British Columbia--(Newsfile Corp. - January 29, 2026) - Galiano Gold Inc. (TSX:GAU) (NYSE:GAU) ("Galiano" or the "Company") is pleased to report the latest results of the 2025 Abore drilling program, which was completed in December 2025 at the Asanko Gold Mine ("AGM") in Ghana, West Africa. Multiple intercepts demonstrate continuity of high-grade zones and step out drilling confirms new high-grade mineralization up to 200 meters ("m") below previous holes. These results demonstrate the robustness of Abore's underground p

    1/29/26 7:30:00 AM ET
    $GAU
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials

    Coffee Holding Company Reports Annual Results.

    STATEN ISLAND, New York, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Coffee Holding Co., Inc. (NASDAQ:JVA) (the "Company," "our" or "we") announced its operating results for the fiscal year ended October 31, 2025.  We are pleased to report to our shareholders the following:  ●Sales of $96.3M, which is up 23% compared to fiscal 2024. ●Net income of $.25 per share, compared to $.39 per share in fiscal 2024. ●Cash dividend of $0.08 per share to be paid to shareholders. Although we successfully increased our revenues by 23% during a turbulent period of market volatility, tariffs and consumer unhappiness with higher retail prices, our net income was negatively affected for multiple reasons. The impact

    1/28/26 5:05:00 PM ET
    $JVA
    Packaged Foods
    Consumer Staples

    Galiano Gold Provides Notice of Fourth Quarter and Full Year 2025 Results

    Vancouver, British Columbia--(Newsfile Corp. - January 9, 2026) - Galiano Gold Inc. (TSX:GAU) (NYSE:GAU) ("Galiano" or the "Company") is pleased to announce it will release its fourth quarter ("Q4") and full year ("FY") 2025 financial and operational results after market close on February 12, 2026. The Company will host a conference call and webcast to review the Q4 and FY results on February 13, 2026, at 7:30am PT.Conference Call DetailsReplay (available until February 20, 2026)Date:February 13, 2026Local:289-819-1450Time:10:30am ET (7:30am PT)Toll Free:1-888-660-6345Dial In:437-900-0527Access Code:68484 #Toll Free:1-888-510-2154 The conference call will be webcast https://app.webinar.net/Q

    1/9/26 8:30:00 AM ET
    $GAU
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials

    $ABOS
    $ACLX
    $AGTC
    $ANGH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Torrid Holdings Inc.

    SC 13G - Torrid Holdings Inc. (0001792781) (Subject)

    12/12/24 6:06:52 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Arcellx Inc.

    SC 13G - Arcellx, Inc. (0001786205) (Subject)

    11/22/24 4:12:28 PM ET
    $ACLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care